Home
About
Overview
Sharing Data
ORCID
Help
History (0)
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Vokes, Everett E.
One or more keywords matched the following items that are connected to
Vokes, Everett E.
Item Type
Name
Concept
Proto-Oncogene Proteins c-met
Academic Article
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.
Academic Article
MET as a target for treatment of chest tumors.
Academic Article
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
Academic Article
Expression and mutational analysis of MET in human solid cancers.
Academic Article
Ethnic differences and functional analysis of MET mutations in lung cancer.
Academic Article
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
Academic Article
MET and phosphorylated MET as potential biomarkers in lung cancer.
Academic Article
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.
Academic Article
Personalized treatment of lung cancer.
Academic Article
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Academic Article
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
Academic Article
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
Academic Article
Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
Academic Article
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.
Academic Article
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.
Academic Article
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
Search Criteria
Proto Oncogene Proteins c met